HCB News: Can you share insights from the clinical studies you conducted and how the results impact patient outcomes and the adoption of your device?
ZE: We are very encouraged by the results from the Jewel IDE Study, which assessed the safety and effectiveness of the device in patients at risk for sudden cardiac arrest. Results from the study have been accepted as Featured Science at the AHA Annual Scientific Sessions. The data is embargoed in advance of publication so I can’t share the details, but those will be available publicly starting November 13th.

HCB News: What are your expectations for the adoption of your device among healthcare professionals, and how do you believe it will impact the standard of care for patients at risk of sudden cardiac arrest?
ZE: We anticipate strong adoption of our device among healthcare professionals, primarily because the device addresses the key limitation of compliance. Physicians have expressed confidence in the device, and many believe that it will become a first-line solution for patients at risk of sudden cardiac arrest. It can be discreetly worn, and patients are more likely to use it consistently due to its comfort and convenience. We believe that the Jewel has the potential to become a standard of care and give patients a better chance for the best possible outcome should they experience sudden cardiac arrest.

HCB News: Can you share any insights about WCDs regarding patients recovering heart function and no longer needing an ICD (implantable cardioverter-defibrillator)?
ZE: Patients who initially are at risk for sudden cardiac arrest may not need an implantable cardioverter defibrillator (ICD) in the longer term due to recovery of heart function. Today, the likelihood of this happening has increased thanks to advances in treatments for heart failure. If patients will actually wear the WCD during this initial period of higher risk,, there is the potential that we can give them the time they need to allow the healing process to progress and potentially avoid unnecessary ICD implantation. This underscores the importance of having a temporary, wearable solution that can adapt to the changing needs of patients.

HCB News: How do you envision the impact of your device on healthcare systems and the patient experience, particularly in the context of temporary risks and long-term management?
ZE: Our device has the potential to positively impact healthcare systems and patient experiences by helping health care providers offer a life-saving solution for patients at risk for sudden cardiac arrest. It offers a seamless and comfortable experience that fits into the lifestyle of patients. It empowers patients to take control of their health while maintaining a high quality of life. Some of these patients are on the path to recovery and can use our device as a temporary solution until their risk diminishes. This not only improves patient outcomes but also reduces the unnecessary burden on healthcare systems by avoiding premature ICD implantations.

Cardiology Homepage